Hims & Hers Health, Inc. (NYSE:HIMS) Stock Holdings Boosted by Farallon Capital Management LLC

Farallon Capital Management LLC increased its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 64,338.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,377,000 shares of the company's stock after purchasing an additional 8,364,000 shares during the period. Farallon Capital Management LLC owned 3.83% of Hims & Hers Health worth $202,556,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Crewe Advisors LLC acquired a new stake in shares of Hims & Hers Health in the 4th quarter worth $28,000. Raleigh Capital Management Inc. increased its holdings in shares of Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after purchasing an additional 1,100 shares in the last quarter. Blume Capital Management Inc. increased its holdings in shares of Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after purchasing an additional 600 shares in the last quarter. Smartleaf Asset Management LLC increased its holdings in shares of Hims & Hers Health by 4,415.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after purchasing an additional 1,413 shares in the last quarter. Finally, Summit Securities Group LLC purchased a new position in shares of Hims & Hers Health in the 4th quarter valued at about $38,000. Institutional investors and hedge funds own 63.52% of the company's stock.

Analyst Ratings Changes

HIMS has been the subject of several recent research reports. TD Cowen downgraded shares of Hims & Hers Health from a "buy" rating to a "hold" rating and dropped their target price for the company from $44.00 to $30.00 in a report on Tuesday, April 29th. Morgan Stanley dropped their target price on shares of Hims & Hers Health from $60.00 to $40.00 and set an "equal weight" rating for the company in a report on Tuesday, April 29th. Bank of America raised their price target on shares of Hims & Hers Health from $22.00 to $26.00 and gave the stock an "underperform" rating in a research note on Tuesday, April 29th. Piper Sandler reaffirmed a "neutral" rating and set a $39.00 price target (up from $35.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Hims & Hers Health in a research note on Wednesday, May 7th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $37.67.

Hims & Hers Health Stock Up 6.3%

Shares of HIMS traded up $3.28 during mid-day trading on Monday, hitting $55.24. The company had a trading volume of 59,143,224 shares, compared to its average volume of 18,512,096. The business's 50-day simple moving average is $32.97 and its 200-day simple moving average is $32.51. Hims & Hers Health, Inc. has a 1-year low of $12.07 and a 1-year high of $72.98. The stock has a market cap of $12.36 billion, a PE ratio of 125.54 and a beta of 1.84.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.12 by $0.08. The company had revenue of $586.01 million for the quarter, compared to analyst estimates of $535.21 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business's quarterly revenue was up 110.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.05 earnings per share. On average, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Buying and Selling

In other Hims & Hers Health news, insider Soleil Boughton sold 4,152 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total transaction of $251,984.88. Following the completion of the sale, the insider now owns 157,345 shares in the company, valued at $9,549,268.05. The trade was a 2.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Andrew Dudum sold 128,127 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $58.27, for a total transaction of $7,465,960.29. Following the sale, the chief executive officer now owns 97,687 shares of the company's stock, valued at approximately $5,692,221.49. The trade was a 56.74% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 631,660 shares of company stock worth $24,978,043. Insiders own 13.71% of the company's stock.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.